## UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of	) MAIL STOP AMENDMENT
Nicholas S. Bodor et al.	) Group Art Unit: 1614
Application No.: 10/551,205	) Examiner: Jonathan S. LAU
Filed: November 14, 2006	) Confirmation No.: 4092
For: ORAL FORMULATIONS OF CLADRIBINE	) ) )

## FOURTH INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98. Applicants request the Examiner's consideration of the document listed on the accompanying Form PTO-1449.

Pursuant to 37 C.F.R. § 1.98, a copy of the document listed is enclosed.

The document is being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since this document is being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

It is respectfully requested that an Examiner-initialed copy of the accompanying Form PTO-1449 be returned to the undersigned.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

By:

Respectfully submitted,

**BUCHANAN INGERSOLL & ROONEY PC** 

Date: January 4, 2008

Registration No. 26254

P.O. Box 1404 Alexandria, VA 22313-1404 703 836 6620

Buchanan Ingersoll & Rooney PC Attorneys & Government Relations Professionals